Healio compiles top hidradenitis suppurativa articles from 2024

Key takeaways:

• New FDA-approved treatments for hidradenitis suppurativa topped the list.
• Content from conferences followed closely behind.

As the year comes to a close, Healio Dermatology has assembled this year’s top hidradenitis suppurativa articles.

FDA approves Bimzelx for adults with moderate to severe hidradenitis suppurativa

In November, the FDA approved Bimzelx for the treatment of moderate to severe HS in adults. Jennifer Hsiao, MD, associate professor of dermatology at Keck School of Medicine of University of Southern California, gave her perspective. Read more.

Physician shares alternative medicine practices for hidradenitis suppurativa

The implementation of dietary modifications, supplementation and other lifestyle changes can significantly improve HS, according to a speaker at the American Academy of Dermatology Annual Meeting. Read more.

VIDEO: ‘A lot of enthusiasm’ in hidradenitis suppurativa research

HS research reportedly hit roadblocks including high placebo responses and difficulty in accurate assessments, according to Amit Garg, MD, professor and chair of the department of dermatology at Northwell Health, but dermatologists are holding out hope for new treatments. Read more.

Hidradenitis suppurativa linked to adverse maternal, offspring outcomes

HS was linked to adverse maternal and offspring outcomes during the peripartum period and in the long-term. Nathalie Auger, MD, MSc, clinical professor at the National Institute of Public Health of Quebec in Canada, weighed in. Read more.

Semaglutide improves hidradenitis suppurativa outcomes

Semaglutide was shown to reduce HS flares in patients with obesity, according to a study presented at the European Academy of Dermatology and Venereology meeting this year. Jennifer Hsiao, MD, associate professor of dermatology at Keck School of Medicine of University of Southern California, weighed in. Read more.

Bimekizumab produces rapid, clinically meaningful responses in hidradenitis suppurativa

Patients treated with bimekizumab for moderate to severe HS exhibited rapid and clinically meaningful responses that were maintained up to 48 weeks. Alexa B. Kimball, MD, MPH, president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, professor of dermatology at Harvard Medical School and lead investigator of the study, offered her insights. Read more.

‘There are options’: Managing hidradenitis suppurativa during pregnancy

It is important for both patients and dermatologists to know that there are options for the management of HS during pregnancy, according to a presentation at the American Academy of Dermatology Annual Meeting. Healio spoke with Katrina Lee, MD, FAAD, clinical assistant professor of dermatology at Keck School of Medicine of University of Southern California, about the presentation. Read more.

Orismilast may improve hidradenitis suppurativa with dose-dependent tolerability

Orismilast may improve mild to severe HS; however, further studies are needed to confirm patient tolerability in this indication, according to a study. Read more.

FDA accepts supplemental BLAs for Bimzelx for hidradenitis suppurativa, 2 mL device

Supplemental biologics license applications for Bimzelx for the treatment of HS and a 2 mL autoinjector device for the drug was accepted by the FDA. Read more.

Patients with unresponsive hidradenitis suppurativa find relief with lutikizumab 300 mg

Lutikizumab showed positive results in the treatment of patients with HS that failed anti-TNF treatment, according to a late-breaking presentation at the American Academy of Dermatology Annual Meeting. Read more.